Trial: 201904155

A phase 1b/2a, open label study to evaluate anti-tumor efficacy and safety of rhIL-7-hyFc (NT-I7) in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory high-risk skin cancers

Phase

I/II

Principal Investigator

Ansstas, George

Disease Site

Melanoma, Skin; Other Skin

Learn more about this study at: clinicaltrials.gov